Clinical Trial Update: Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pharmacodynamics, pharmacokinetics, and safety of two doses of CHF6001 DPI in adults with COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF6001

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD | Phase 2 | Status: COMPLETED